# CICC Qichen

> CICC Qichen is a VC fund backing Medical, Health Care and Manufacturing. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 8
- Last investment: Nov 2023
- Lead investor: 13%
- Last updated: Aug 2026

CICC Qichen is a VC fund focused on Medical and Health Care. CICC Qichen

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 4 | 50% |
| Health Care | 4 | 50% |
| Manufacturing | 4 | 50% |
| Biotechnology | 3 | 38% |
| Medical Device | 2 | 25% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 50% |
| Series A | 1 | 13% |
| Series D | 1 | 13% |
| Series F | 1 | 13% |
| Venture - Series Unknown | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tachem | Tachem is a biotechnology company that specializes in the research, development, production, and distribution of products from the protected amino acid series. | $42.3M | Series A | Nov 29, 2023 |  |
| Testi | Testi focuses on semiconductor substrate materials, semiconductor devices, advanced packaging, MEMS, and other fields. They provide system solutions and process equipment for thinning, polishing, and CMP. |  | Series B | Oct 30, 2023 |  |
| Cell Probio | Cell Probio is a manufacturer of cell culture consumables, positioned in the R&D, production and sales of high-end biological consumables. |  | Series B | Sep 16, 2022 |  |
| Helmholtz | Helmholtz is a research and development manufacturer of automotive heat transfer transmission systems. It is dedicated to the development, production and sales of heat transfer transmission systems. It mainly provides users with new energy vehicle thermal management systems, automotive electronic systems and other products. | $39.3M | Series B | Jan 18, 2022 |  |
| Paraview Software | Paraview Software is an enterprise-level IT management platform solution provider with ParaSecure OSC operation and maintenance security management software and ParaSecure AAC security log management system software. |  | Series D | Nov 01, 2021 |  |
| Berry Oncology | Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer.Thecompany's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market. | $99.2M | Series B | Aug 05, 2021 |  |
| Leo Medical Co., Ltd. | Leo Medical is a high-tech medical company that creates, produces, and sells cutting-edge medical products. Leo Medical develops medical devices that use cutting-edge biomedical technology to aid in the diagnosis, intervention, and treatment of disorders of the digestive and circulatory systems. They feel that a minimally invasive technique is themost humane way to treat patients while without sacrificing the procedure's quality. Minimal invasion in medical treatments frequently allows patients to heal faster and doctors to simplify medical operations. It is a win-win situation for everyone.Leo Medical was founded in 2011 and is headquartered in Jiangsu, P.R. China. | $15.5M | Venture - Series Unknown | Jun 28, 2021 |  |
| CF PharmTech | CF PharmTech was founded in 2007, it is a fully independent, dynamic, integrated, specialty pharmaceutical company focused on the development and manufacturing of products for the treatments of asthma, COPD and allergic rhinitis for the global market. Its mission is to develop high-quality and affordable medicine to help patients achieve effectivemanagement care for their respiratory diseases. The headquarters is located in the lakeside of the Caohu District of Suzhou, Jiangsu Province, with many very convenient transportation options available. It only takes thirty minutes by train to Shanghai and four hours by train to Beijing. | $51M | Series F | Jul 01, 2020 |  |

8 of 8 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- Anxin Investment — VC Fund, 1 deal together
- [BAIC Capital](https://shizune.co/investors/profile/baic-capital) — VC Fund, 1 deal together
- Beijing Advanced Fund — VC Fund, 1 deal together
- [Apple Funds](https://shizune.co/investors/profile/beijing-apple-funds-investment) — VC Fund, 1 deal together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does CICC Qichen invest in?

CICC Qichen invests primarily in Medical, Health Care and Manufacturing startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did CICC Qichen last invest?

The most recent investment recorded for CICC Qichen closed in Nov 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co